Please login to the form below

Not currently logged in
Email:
Password:

Spark Therapeutics

This page shows the latest Spark Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Novartis buys gene therapy firm AveXis for $8.7bn

Novartis buys gene therapy firm AveXis for $8.7bn

ex-US rights to Spark Therapeutics’recently-approved Luxturna (voretigene neparvovec-rzyl) for an inherited eye disease. ... The deal also brings a manufacturing facility for gene therapeutics in Libertyville, Illinois.

Latest news

  • Novartis negotiates ex-US rights to Spark gene therapy Novartis negotiates ex-US rights to Spark gene therapy

    Novartis negotiates ex-US rights to Spark gene therapy. Strikes $170m deal for Luxturna. ... Novartis has agreed to develop Spark Therapeutics’recently-approved gene therapy Luxturna outside the US, in a deal valued at $170m.

  • Spark sets Luxturna price, igniting US affordability debate Spark sets Luxturna price, igniting US affordability debate

    After much speculation, Spark Therapeutics has confirmed the price it intends to charge for its sight-saving gene therapy Luxturna - and it’s at the high end of expectations. ... We believe that access to therapy is a shared responsibility among Spark

  • NICE backs GSK’s €594k gene therapy for rare disease NICE backs GSK’s €594k gene therapy for rare disease

    The new guidance comes in the same week that Spark Therapeutics announced its pricing for RPE65-mediated eye disease gene therapy Luxturna of $850, 000 - $425, 000 per eye - kicking off ... fierce debate about how healthcare systems in the US will fund

  • Spark’s Luxturna becomes US’s first approved gene therapy Spark’s Luxturna becomes US’s first approved gene therapy

    Spark’ s Luxturna becomes US’ s first approved gene therapy. FDA says its move 'reinforces the potential of this breakthrough'. ... The FDA has chalked up another first for 2017, approving Spark Therapeutics’gene therapy Luxturna for a

  • Spark closes on first US gene therapy approval Spark closes on first US gene therapy approval

    Spark closes on first US gene therapy approval. FDA starts review of Luxturna for patients with inherited retinal disease. ... The FDA has started its review of Spark Therapeutics' rare eye disease treatment Luxturna which, if approved, will be the first

More from news
Approximately 6 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Health on instalment Health on instalment

    For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.

  • The rise of real-world evidence The rise of real-world evidence

    Spark Therapeutics has a similar arrangement for its gene therapy. These agreements make real-world efficacy a requirement for full payment for a drug.

  • Deal Watch December 2016 Deal Watch December 2016

    and Bicycle Therapeutics at $1bn, and the Purdue Pharma-Exicure deal, at $790m. ... The size of the deals signed by AstraZeneca with Bicycle Therapeutics, by Spark with Selecta Biosciences and by Celgene with Evotec suggest that their technologies

  • Deal Watch August 2016 Deal Watch August 2016

    $14bn, antibiotic business interests from AstraZeneca for $1.4bn and Bamboo Therapeutics for $645m. ... This will help with the collaboration with Spark Therapeutics that is developing a treatment for haemophilia B that incorporates a bio-engineered rAAV

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. † 300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is the UK arm of Zeno Group, a global integrated communications consultancy. Everything we do is rooted...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics